<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01432262</url>
  </required_header>
  <id_info>
    <org_study_id>B1851048</org_study_id>
    <secondary_id>6115A1-3020</secondary_id>
    <nct_id>NCT01432262</nct_id>
  </id_info>
  <brief_title>13-valent Pneumococcal Conjugate Vaccine Study in Adults =&gt; 50 Years of Age in Mexico</brief_title>
  <official_title>A Phase 3, Open Label, Single Arm, Multicenter, Trial to Assess The Safety, Tolerability And Immunogenicity Of 13-Valent Pneumococcal Conjugate Vaccine In Healthy Adults Aged =&gt; 50 Years of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine in Mexico.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study will be to assess the safety, tolerability, and immunogenicity of
      13-Valent Pneumococcal Conjugate Vaccine (13vPnC) when given to healthy adults older than 50
      years of age who haven't received 23-valent pneumococcal polysaccharide vaccine in Mexico.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination</measure>
    <time_frame>One month (28 to 42 days) after vaccination</time_frame>
    <description>Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a quantitative functional OPA assay. Confidence intervals (CIs) for GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers. Individual OPA assay values below the assay LLOQ (lower limit of quantification) were set at a titer of 0.5*limit of detection (LOD [8]) = (titer of 4) for the purpose of calculating the OPA GMT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Local Reactions Within 14 Days After Vaccination</measure>
    <time_frame>Within 14 days after vaccination</time_frame>
    <description>Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present), Mild (2.5 to 5.0 centimeters [cm]), Moderate (5.1 to 10.0 cm), Severe (&gt;10 cm). Pain at injection site scaled as Any (pain present), Mild (does not interfere with activity), Moderate (interferes with activity), Severe (prevents daily activity).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Systemic Events Within 14 Days After Vaccination</measure>
    <time_frame>Within 14 days after vaccination</time_frame>
    <description>Systemic events reported using electronic diary. Fever-Any:&gt;=38 degrees Celsius (C), Mild (M):&gt;=38 to &lt;38.5 degrees C, Moderate(Mod):&gt;=38.5 to &lt;39 degrees C, Severe (S):&gt;=39 to &lt;=40 degrees C, Potentially life threatening:&gt;40 degrees C. Headache, fatigue, muscle pain, joint pain- Any: present, M:did not interfere with activity, Mod:some interference, S:activity prevented. Vomiting- Any:present, M:1-2 times/day (d), Mod:&gt;2/d, S:required intravenous hydration. Diarrhoea- Any:present, M:2-3 loose stools/d, Mod:4-5/d, S:&gt;=6/d. All reports of fever &gt;40 degrees C were confirmed as data entry errors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to 1 Month (28 to 42 days) after vaccination</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between vaccination and up to 1 month (28 to 42 days) after vaccination that were absent before treatment or that worsened relative to pre-treatment state.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Serotype-Specific Opsonophagocytic Activity (OPA) Titer With at Least Lower Limit of Quantification (LLOQ) 1 Month After Vaccination</measure>
    <time_frame>One month (28 to 42 days) after vaccination</time_frame>
    <description>Percentage of participants achieving OPA GMTs with at least LLOQ for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) determined in blood samples of all participants using microcolony OPA assay. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=1:18, 3=1:12, 4=1:21, 5=1:29, 6A=1:37, 6B=1:43, 7F=1:210, 9V=1:345, 14=1:35, 18C=1:31, 19A=1:18, 19F=1:48, 23F=1:13.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From Pre-Vaccination to 1 Month Post-Vaccination</measure>
    <time_frame>Pre-vaccination to 1 month (28 to 42 days) after vaccination</time_frame>
    <description>Geometric mean fold rises (GMFRs) for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from pre-vaccination to 1 month post-vaccination were computed using the logarithmically transformed assay results. CIs for GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">324</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>=&gt; 65 years of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 to 64 years of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>vaccine-13vPnC</intervention_name>
    <description>Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>13-valent pneumococcal conjugate vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>vaccine-13vPnC</intervention_name>
    <description>Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>13-valent pneumococcal conjugate vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female older than 50 years of age

          -  Eligibility must be determined by medical history, physical exam and clinical judgment

          -  Able to complete an electronic diary

          -  Available for duration of study

          -  Negative pregnancy test for subjects in group 2 age 50 to 64 years

          -  Practice abstinence or use reliable birth control if age is 50 to 64 years

        Exclusion Criteria:

          -  History of allergic reaction to any vaccine

          -  Previous vaccination with licensed or experimental pneumococcal vaccine

          -  S. pneumonia infection within past 5 years before investigational product
             administration

          -  Known or suspected immunodeficiency or received treatment including cytotoxic agents
             or systemic corticosteroids, serious chronic disorder such as malignancy cancer

          -  Receipt of plasma products or immunoglobulins within 60 days

          -  Bleeding conditions or diathesis

          -  Receipt of investigational product within 28 days before study entry

          -  Other severe acute or chronic medical or psychiatric condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Mexicano de Investigación Clínica, S.A. de C.V</name>
      <address>
        <city>Mexico</city>
        <state>D.f.</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</name>
      <address>
        <city>Mexico</city>
        <state>DF</state>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Star Medica</name>
      <address>
        <city>Morelia</city>
        <state>Michoacan</state>
        <zip>CP 58070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Durango</name>
      <address>
        <city>Durango</city>
        <zip>34000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1851048&amp;StudyName=13-valent%20Pneumococcal%20Conjugate%20Vaccine%20Study%20in%20Adults%20%3D%3E%2050%20Years%20of%20Age%20in%20Mexico</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2011</study_first_submitted>
  <study_first_submitted_qc>September 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2011</study_first_posted>
  <results_first_submitted>December 4, 2012</results_first_submitted>
  <results_first_submitted_qc>December 4, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 8, 2013</results_first_posted>
  <last_update_submitted>January 18, 2013</last_update_submitted>
  <last_update_submitted_qc>January 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prevention of pneumococcal diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>13vPnC, Cohort 1</title>
          <description>Participants 50 to 64 years of age received 13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>13vPnC, Cohort 2</title>
          <description>Participants greater than or equal to (&gt;=) 65 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="161"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="161"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>13vPnC, Cohort 1</title>
          <description>Participants 50 to 64 years of age received 13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>13vPnC, Cohort 2</title>
          <description>Participants greater than or equal to (&gt;=) 65 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="162"/>
            <count group_id="B2" value="161"/>
            <count group_id="B3" value="323"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.7" spread="4.0"/>
                    <measurement group_id="B2" value="73.4" spread="5.8"/>
                    <measurement group_id="B3" value="64.5" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination</title>
        <description>Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a quantitative functional OPA assay. Confidence intervals (CIs) for GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers. Individual OPA assay values below the assay LLOQ (lower limit of quantification) were set at a titer of 0.5*limit of detection (LOD [8]) = (titer of 4) for the purpose of calculating the OPA GMT.</description>
        <time_frame>One month (28 to 42 days) after vaccination</time_frame>
        <population>Evaluable Immunogenicity Population (EIP): eligible participants who received vaccine, had blood drawn within the pre-specified time frames, had at least 1 valid and determinate assay result for proposed analysis, received no prohibited vaccines, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, Cohort 1</title>
            <description>Participants 50 to 64 years of age received 13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, Cohort 2</title>
            <description>Participants greater than or equal to (&gt;=) 65 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination</title>
          <description>Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a quantitative functional OPA assay. Confidence intervals (CIs) for GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers. Individual OPA assay values below the assay LLOQ (lower limit of quantification) were set at a titer of 0.5*limit of detection (LOD [8]) = (titer of 4) for the purpose of calculating the OPA GMT.</description>
          <population>Evaluable Immunogenicity Population (EIP): eligible participants who received vaccine, had blood drawn within the pre-specified time frames, had at least 1 valid and determinate assay result for proposed analysis, received no prohibited vaccines, and had no other major protocol violations.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" lower_limit="92.3" upper_limit="155.3"/>
                    <measurement group_id="O2" value="84" lower_limit="62.8" upper_limit="112.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="72.4" upper_limit="106.9"/>
                    <measurement group_id="O2" value="89" lower_limit="70.8" upper_limit="111.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1729" lower_limit="1377.6" upper_limit="2170.9"/>
                    <measurement group_id="O2" value="1209" lower_limit="977.1" upper_limit="1495.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288" lower_limit="208.6" upper_limit="398.3"/>
                    <measurement group_id="O2" value="285" lower_limit="208.7" upper_limit="388.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3380" lower_limit="2732.9" upper_limit="4179.6"/>
                    <measurement group_id="O2" value="3343" lower_limit="2625.2" upper_limit="4256.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3982" lower_limit="3273.2" upper_limit="4845.0"/>
                    <measurement group_id="O2" value="3384" lower_limit="2708.6" upper_limit="4227.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3130" lower_limit="2660.9" upper_limit="3681.4"/>
                    <measurement group_id="O2" value="1929" lower_limit="1564.7" upper_limit="2378.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2416" lower_limit="1901.0" upper_limit="3071.4"/>
                    <measurement group_id="O2" value="1402" lower_limit="1030.8" upper_limit="1906.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1569" lower_limit="1267.9" upper_limit="1940.3"/>
                    <measurement group_id="O2" value="1316" lower_limit="1068.9" upper_limit="1619.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3063" lower_limit="2405.9" upper_limit="3900.7"/>
                    <measurement group_id="O2" value="2197" lower_limit="1727.2" upper_limit="2794.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1542" lower_limit="1257.9" upper_limit="1889.0"/>
                    <measurement group_id="O2" value="1196" lower_limit="990.6" upper_limit="1443.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1104" lower_limit="828.1" upper_limit="1473.1"/>
                    <measurement group_id="O2" value="1188" lower_limit="905.0" upper_limit="1558.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="879" lower_limit="650.3" upper_limit="1187.7"/>
                    <measurement group_id="O2" value="930" lower_limit="667.1" upper_limit="1296.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Pre-Specified Local Reactions Within 14 Days After Vaccination</title>
        <description>Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present), Mild (2.5 to 5.0 centimeters [cm]), Moderate (5.1 to 10.0 cm), Severe (&gt;10 cm). Pain at injection site scaled as Any (pain present), Mild (does not interfere with activity), Moderate (interferes with activity), Severe (prevents daily activity).</description>
        <time_frame>Within 14 days after vaccination</time_frame>
        <population>Safety Population included all participants who received vaccine. N (Number of Participants Analyzed)=participants reporting yes for at least 1 day or no for all 14 days and n=participants reporting yes for at least 1 day or no for all 14 days for specified local reaction for each group respectively. Participants may be represented in &gt;1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, Cohort 1</title>
            <description>Participants 50 to 64 years of age received 13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, Cohort 2</title>
            <description>Participants greater than or equal to (&gt;=) 65 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Local Reactions Within 14 Days After Vaccination</title>
          <description>Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present), Mild (2.5 to 5.0 centimeters [cm]), Moderate (5.1 to 10.0 cm), Severe (&gt;10 cm). Pain at injection site scaled as Any (pain present), Mild (does not interfere with activity), Moderate (interferes with activity), Severe (prevents daily activity).</description>
          <population>Safety Population included all participants who received vaccine. N (Number of Participants Analyzed)=participants reporting yes for at least 1 day or no for all 14 days and n=participants reporting yes for at least 1 day or no for all 14 days for specified local reaction for each group respectively. Participants may be represented in &gt;1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness: Any (n=125, 120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" lower_limit="8.8" upper_limit="21.8"/>
                    <measurement group_id="O2" value="15.8" lower_limit="9.8" upper_limit="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild (n=124, 120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" lower_limit="5.1" upper_limit="16.3"/>
                    <measurement group_id="O2" value="13.3" lower_limit="7.8" upper_limit="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate (n=125, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" lower_limit="4.5" upper_limit="15.2"/>
                    <measurement group_id="O2" value="7.0" lower_limit="3.1" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe (n=125, 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="0.5" upper_limit="6.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any (n=130, 120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" lower_limit="14.8" upper_limit="29.6"/>
                    <measurement group_id="O2" value="13.3" lower_limit="7.8" upper_limit="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild (n=127, 120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" lower_limit="11.8" upper_limit="25.9"/>
                    <measurement group_id="O2" value="11.7" lower_limit="6.5" upper_limit="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate (n=127, 114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="4.4" upper_limit="15.0"/>
                    <measurement group_id="O2" value="4.4" lower_limit="1.4" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe (n=125, 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="0.5" upper_limit="6.9"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site: Any (n=151, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5" lower_limit="67.8" upper_limit="82.1"/>
                    <measurement group_id="O2" value="60.6" lower_limit="51.9" upper_limit="68.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site: Mild (n=151, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.2" lower_limit="66.4" upper_limit="80.9"/>
                    <measurement group_id="O2" value="60.3" lower_limit="51.6" upper_limit="68.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site: Moderate (n=130, 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" lower_limit="14.8" upper_limit="29.6"/>
                    <measurement group_id="O2" value="8.5" lower_limit="4.2" upper_limit="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site: Severe (n=125, 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="0.9" upper_limit="8.0"/>
                    <measurement group_id="O2" value="3.5" lower_limit="1.0" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Pre-Specified Systemic Events Within 14 Days After Vaccination</title>
        <description>Systemic events reported using electronic diary. Fever-Any:&gt;=38 degrees Celsius (C), Mild (M):&gt;=38 to &lt;38.5 degrees C, Moderate(Mod):&gt;=38.5 to &lt;39 degrees C, Severe (S):&gt;=39 to &lt;=40 degrees C, Potentially life threatening:&gt;40 degrees C. Headache, fatigue, muscle pain, joint pain- Any: present, M:did not interfere with activity, Mod:some interference, S:activity prevented. Vomiting- Any:present, M:1-2 times/day (d), Mod:&gt;2/d, S:required intravenous hydration. Diarrhoea- Any:present, M:2-3 loose stools/d, Mod:4-5/d, S:&gt;=6/d. All reports of fever &gt;40 degrees C were confirmed as data entry errors.</description>
        <time_frame>Within 14 days after vaccination</time_frame>
        <population>Safety Population included all participants who received vaccine. N (Number of Participants Analyzed)=participants reporting yes for at least 1 day or no for all 14 days and n=participants reporting yes for at least 1 day or no for all 14 days for specified systemic event for each group respectively. Participants may be represented in &gt;1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, Cohort 1</title>
            <description>Participants 50 to 64 years of age received 13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, Cohort 2</title>
            <description>Participants greater than or equal to (&gt;=) 65 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Systemic Events Within 14 Days After Vaccination</title>
          <description>Systemic events reported using electronic diary. Fever-Any:&gt;=38 degrees Celsius (C), Mild (M):&gt;=38 to &lt;38.5 degrees C, Moderate(Mod):&gt;=38.5 to &lt;39 degrees C, Severe (S):&gt;=39 to &lt;=40 degrees C, Potentially life threatening:&gt;40 degrees C. Headache, fatigue, muscle pain, joint pain- Any: present, M:did not interfere with activity, Mod:some interference, S:activity prevented. Vomiting- Any:present, M:1-2 times/day (d), Mod:&gt;2/d, S:required intravenous hydration. Diarrhoea- Any:present, M:2-3 loose stools/d, Mod:4-5/d, S:&gt;=6/d. All reports of fever &gt;40 degrees C were confirmed as data entry errors.</description>
          <population>Safety Population included all participants who received vaccine. N (Number of Participants Analyzed)=participants reporting yes for at least 1 day or no for all 14 days and n=participants reporting yes for at least 1 day or no for all 14 days for specified systemic event for each group respectively. Participants may be represented in &gt;1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: Any (n=126, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="0.5" upper_limit="6.8"/>
                    <measurement group_id="O2" value="10.2" lower_limit="5.4" upper_limit="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Mild (n=126, 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.2" upper_limit="5.6"/>
                    <measurement group_id="O2" value="3.5" lower_limit="1.0" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Moderate (n=125, 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.0" upper_limit="4.4"/>
                    <measurement group_id="O2" value="1.8" lower_limit="0.2" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Severe (n=124, 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.0" upper_limit="4.4"/>
                    <measurement group_id="O2" value="1.8" lower_limit="0.2" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Potentially life threatening (n=124, 116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="2.9"/>
                    <measurement group_id="O2" value="4.3" lower_limit="1.4" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Any (n=144, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.2" lower_limit="38.9" upper_limit="55.7"/>
                    <measurement group_id="O2" value="38.6" lower_limit="30.3" upper_limit="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Mild (n=142, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.4" lower_limit="31.3" upper_limit="48.0"/>
                    <measurement group_id="O2" value="36.2" lower_limit="27.9" upper_limit="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Moderate (n=134, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9" lower_limit="19.6" upper_limit="35.2"/>
                    <measurement group_id="O2" value="20.0" lower_limit="13.4" upper_limit="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Severe (n=126, 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="2.8" upper_limit="12.1"/>
                    <measurement group_id="O2" value="5.3" lower_limit="2.0" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Any (n=140, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3" lower_limit="35.9" upper_limit="52.9"/>
                    <measurement group_id="O2" value="32.6" lower_limit="24.6" upper_limit="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Mild (n=140, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3" lower_limit="31.1" upper_limit="47.9"/>
                    <measurement group_id="O2" value="30.5" lower_limit="22.6" upper_limit="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Moderate (n=129, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" lower_limit="12.3" upper_limit="26.4"/>
                    <measurement group_id="O2" value="16.0" lower_limit="9.9" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Severe (n=126, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="1.3" upper_limit="9.0"/>
                    <measurement group_id="O2" value="5.2" lower_limit="1.9" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Any (n=125, 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="1.3" upper_limit="9.1"/>
                    <measurement group_id="O2" value="1.8" lower_limit="0.2" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Mild (n=125, 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="0.9" upper_limit="8.0"/>
                    <measurement group_id="O2" value="1.8" lower_limit="0.2" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Moderate (n=124, 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.2" upper_limit="5.7"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Severe (n=124, 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="2.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Any (n=134, 120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" lower_limit="18.9" upper_limit="34.4"/>
                    <measurement group_id="O2" value="15.0" lower_limit="9.1" upper_limit="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Mild (n=129, 120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" lower_limit="16.3" upper_limit="31.5"/>
                    <measurement group_id="O2" value="14.2" lower_limit="8.5" upper_limit="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Moderate (n=129, 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" lower_limit="2.7" upper_limit="11.9"/>
                    <measurement group_id="O2" value="1.8" lower_limit="0.2" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Severe (n=125, 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.0" upper_limit="4.4"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.0" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain: Any (n=147, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5" lower_limit="52.2" upper_limit="68.5"/>
                    <measurement group_id="O2" value="43.9" lower_limit="35.3" upper_limit="52.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain: Mild (n=146, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.6" lower_limit="51.2" upper_limit="67.6"/>
                    <measurement group_id="O2" value="40.3" lower_limit="31.8" upper_limit="49.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain: Moderate (n=132, 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5" lower_limit="16.5" upper_limit="31.6"/>
                    <measurement group_id="O2" value="19.5" lower_limit="12.9" upper_limit="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain: Severe (n=125, 116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="2.3" upper_limit="11.2"/>
                    <measurement group_id="O2" value="6.0" lower_limit="2.5" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Any (n=139, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3" lower_limit="27.3" upper_limit="43.8"/>
                    <measurement group_id="O2" value="33.3" lower_limit="25.3" upper_limit="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Mild (n=137, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7" lower_limit="23.1" upper_limit="39.1"/>
                    <measurement group_id="O2" value="29.9" lower_limit="22.1" upper_limit="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Moderate (n=130, 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" lower_limit="7.8" upper_limit="20.1"/>
                    <measurement group_id="O2" value="17.1" lower_limit="10.9" upper_limit="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Severe (n=125, 116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="1.3" upper_limit="9.1"/>
                    <measurement group_id="O2" value="5.2" lower_limit="1.9" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of medication to treat fever (n=129, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" lower_limit="6.7" upper_limit="18.5"/>
                    <measurement group_id="O2" value="13.6" lower_limit="8.0" upper_limit="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of medication to treat pain (n=130, 121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" lower_limit="8.4" upper_limit="21.0"/>
                    <measurement group_id="O2" value="12.4" lower_limit="7.1" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between vaccination and up to 1 month (28 to 42 days) after vaccination that were absent before treatment or that worsened relative to pre-treatment state.</description>
        <time_frame>Baseline up to 1 Month (28 to 42 days) after vaccination</time_frame>
        <population>Safety Population included all participants who received the vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, Cohort 1</title>
            <description>Participants 50 to 64 years of age received 13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, Cohort 2</title>
            <description>Participants greater than or equal to (&gt;=) 65 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</title>
          <description>An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between vaccination and up to 1 month (28 to 42 days) after vaccination that were absent before treatment or that worsened relative to pre-treatment state.</description>
          <population>Safety Population included all participants who received the vaccine.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="6.7" upper_limit="17.0"/>
                    <measurement group_id="O2" value="6.2" lower_limit="3.0" upper_limit="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.2" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Serotype-Specific Opsonophagocytic Activity (OPA) Titer With at Least Lower Limit of Quantification (LLOQ) 1 Month After Vaccination</title>
        <description>Percentage of participants achieving OPA GMTs with at least LLOQ for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) determined in blood samples of all participants using microcolony OPA assay. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=1:18, 3=1:12, 4=1:21, 5=1:29, 6A=1:37, 6B=1:43, 7F=1:210, 9V=1:345, 14=1:35, 18C=1:31, 19A=1:18, 19F=1:48, 23F=1:13.</description>
        <time_frame>One month (28 to 42 days) after vaccination</time_frame>
        <population>EIP: eligible participants who received vaccine, had blood drawn within the pre-specified time frames, had at least 1 valid and determinate assay result for proposed analysis, received no prohibited vaccines, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, Cohort 1</title>
            <description>Participants 50 to 64 years of age received 13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, Cohort 2</title>
            <description>Participants greater than or equal to (&gt;=) 65 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Serotype-Specific Opsonophagocytic Activity (OPA) Titer With at Least Lower Limit of Quantification (LLOQ) 1 Month After Vaccination</title>
          <description>Percentage of participants achieving OPA GMTs with at least LLOQ for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) determined in blood samples of all participants using microcolony OPA assay. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=1:18, 3=1:12, 4=1:21, 5=1:29, 6A=1:37, 6B=1:43, 7F=1:210, 9V=1:345, 14=1:35, 18C=1:31, 19A=1:18, 19F=1:48, 23F=1:13.</description>
          <population>EIP: eligible participants who received vaccine, had blood drawn within the pre-specified time frames, had at least 1 valid and determinate assay result for proposed analysis, received no prohibited vaccines, and had no other major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.3" lower_limit="84.5" upper_limit="94.5"/>
                    <measurement group_id="O2" value="81.0" lower_limit="74.0" upper_limit="86.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.8" lower_limit="90.0" upper_limit="97.7"/>
                    <measurement group_id="O2" value="90.1" lower_limit="84.2" upper_limit="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="93.4" upper_limit="99.3"/>
                    <measurement group_id="O2" value="98.7" lower_limit="95.3" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.2" lower_limit="83.0" upper_limit="93.7"/>
                    <measurement group_id="O2" value="90.8" lower_limit="85.0" upper_limit="94.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="95.4" upper_limit="99.8"/>
                    <measurement group_id="O2" value="98.1" lower_limit="94.6" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="96.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="98.7" lower_limit="95.5" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="96.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="97.5" lower_limit="93.6" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.8" lower_limit="92.6" upper_limit="98.9"/>
                    <measurement group_id="O2" value="92.3" lower_limit="86.9" upper_limit="95.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" lower_limit="94.4" upper_limit="99.6"/>
                    <measurement group_id="O2" value="98.1" lower_limit="94.5" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" lower_limit="94.4" upper_limit="99.6"/>
                    <measurement group_id="O2" value="98.7" lower_limit="95.4" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="96.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.4" lower_limit="96.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.4" lower_limit="90.7" upper_limit="98.1"/>
                    <measurement group_id="O2" value="96.0" lower_limit="91.5" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.2" lower_limit="89.2" upper_limit="97.3"/>
                    <measurement group_id="O2" value="91.7" lower_limit="86.2" upper_limit="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From Pre-Vaccination to 1 Month Post-Vaccination</title>
        <description>Geometric mean fold rises (GMFRs) for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from pre-vaccination to 1 month post-vaccination were computed using the logarithmically transformed assay results. CIs for GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
        <time_frame>Pre-vaccination to 1 month (28 to 42 days) after vaccination</time_frame>
        <population>EIP: eligible participants who received vaccine, had blood drawn within the pre-specified time frames, had at least 1 valid and determinate assay result, received no prohibited vaccines, and had no other major protocol violations. Here “N” signifies participants with valid and determinate assay results at both pre-vaccination and post-vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, Cohort 1</title>
            <description>Participants 50 to 64 years of age received 13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, Cohort 2</title>
            <description>Participants greater than or equal to (&gt;=) 65 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From Pre-Vaccination to 1 Month Post-Vaccination</title>
          <description>Geometric mean fold rises (GMFRs) for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from pre-vaccination to 1 month post-vaccination were computed using the logarithmically transformed assay results. CIs for GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
          <population>EIP: eligible participants who received vaccine, had blood drawn within the pre-specified time frames, had at least 1 valid and determinate assay result, received no prohibited vaccines, and had no other major protocol violations. Here “N” signifies participants with valid and determinate assay results at both pre-vaccination and post-vaccination.</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" lower_limit="16.17" upper_limit="28.16"/>
                    <measurement group_id="O2" value="11.7" lower_limit="8.70" upper_limit="15.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="9.77" upper_limit="16.05"/>
                    <measurement group_id="O2" value="7.8" lower_limit="6.03" upper_limit="10.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.7" lower_limit="36.40" upper_limit="91.36"/>
                    <measurement group_id="O2" value="19.9" lower_limit="13.23" upper_limit="29.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3" lower_limit="26.06" upper_limit="53.47"/>
                    <measurement group_id="O2" value="26.2" lower_limit="18.74" upper_limit="36.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.3" lower_limit="39.00" upper_limit="99.36"/>
                    <measurement group_id="O2" value="28.7" lower_limit="19.76" upper_limit="41.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" lower_limit="11.61" upper_limit="28.15"/>
                    <measurement group_id="O2" value="9.4" lower_limit="6.61" upper_limit="13.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2" lower_limit="26.94" upper_limit="69.17"/>
                    <measurement group_id="O2" value="15.5" lower_limit="10.05" upper_limit="23.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" lower_limit="5.72" upper_limit="13.43"/>
                    <measurement group_id="O2" value="7.2" lower_limit="4.72" upper_limit="10.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="3.73" upper_limit="7.56"/>
                    <measurement group_id="O2" value="3.4" lower_limit="2.58" upper_limit="4.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3" lower_limit="28.19" upper_limit="69.51"/>
                    <measurement group_id="O2" value="13.9" lower_limit="9.21" upper_limit="21.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" lower_limit="21.19" upper_limit="42.50"/>
                    <measurement group_id="O2" value="11.2" lower_limit="7.99" upper_limit="15.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.8" lower_limit="28.33" upper_limit="64.67"/>
                    <measurement group_id="O2" value="20.8" lower_limit="13.38" upper_limit="32.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.6" lower_limit="43.16" upper_limit="93.75"/>
                    <measurement group_id="O2" value="35.8" lower_limit="24.16" upper_limit="52.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events: recorded from signing of informed consent form to 28-42 days post 13vPnC. Participants recorded pre-specified AEs in electronic diary: local reactions and systemic events from Day 1 to 14 post 13vPnC.</time_frame>
      <desc>SAEs and AEs were grouped by system organ class and summarized. AEs included solicited AEs collected in the electronic diary (local and systemic reactions; systematic assessment) and unsolicited events collected on the case report form at each visit (nonsystematic assessment).</desc>
      <group_list>
        <group group_id="E1">
          <title>13vPnC, Cohort 1</title>
          <description>Participants 50 to 64 years of age received 13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>13vPnC, Cohort 2</title>
          <description>Participants greater than or equal to (&gt;=) 65 years of age received 13vPnC administered as a 0.5 mL single dose intramuscularly on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Systemic Events</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 15.0">Aphthous stomatitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 15.0">Constipation</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 15.0">Nausea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 15.0">Asthenia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 15.0">Influenza like illness</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Fever Any</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Fever Mild</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Fever Moderate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Fever Severe</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Fever Potentially life threatening</sub_title>
                <description>All 'Fever Potentially life threatening' events were confirmed as data entry errors.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Fatigue Any</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Fatigue Mild</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Fatigue Moderate</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Fatigue Severe</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Headache Any</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Headache Mild</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Headache Moderate</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Headache Severe</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Vomiting Any</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Vomiting Mild</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Vomiting Moderate</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Vomiting Severe</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Diarrhea Any</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Diarrhea Mild</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Diarrhea Moderate</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Diarrhea Severe</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Muscle pain Any</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Muscle pain Mild</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Muscle pain Moderate</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Muscle pain Severe</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Joint pain Any</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Joint pain Mild</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Joint pain Moderate</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Joint pain Severe</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 15.0">Gastroenteritis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 15.0">Gastrointestinal infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 15.0">Influenza</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 15.0">Laryngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 15.0">Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 15.0">Otitis media acute</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 15.0">Pharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 15.0">Rhinitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 15.0">Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 15.0">Urinary tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 15.0">Limb injury</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 15.0">Musculoskeletal chest pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 15.0">Neck pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 15.0">Pain in extremity</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 15.0">Dizziness</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 15.0">Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 15.0">Libido decreased</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 15.0">Urethral pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 15.0">Vaginal haemorrhage</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 15.0">Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Local Reactions">Redness Any</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness Mild</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness Moderate</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness Severe</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling Any</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling Mild</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling Moderate</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling Severe</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Pain at injection site Any</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Pain at injection site Mild</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Pain at injection site Moderate</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Pain at injection site Severe</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 15.0">Hypertension</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

